ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the US and expanding into the EU. The SmartFlow® cannula is being used in partnership with over 20 biologics & drug delivery companies in various stages from preclinical research to late stage regulatory trials. More than 4,000 cases have been supported by our field-based clinical specialist team which offers support and services for our partners.
Renishaw Neuro Solutions enables direct-to-target delivery for a broad range of applications. Using the neuroinfuse™ drug delivery system, predictable and translatable gene therapy infusions in preclinical and clinical trials can become a reality. Our Lab2Clinic™ service supports pharma through the preclinical journey, translation into clinical trials and scaled-up commercialisation. We have a wide geographical reach and we focus on promoting long-term partnerships. All this is underpinned by our FDA-cleared, CE-marked stereotactic products borne out of a +45-year precision engineering heritage.
Biomere is a global, nonclinical contract research organization (CRO) with locations on the east and west coast, as well as multiple locations in China (JOINN). We specialize in solving preclinical challenges with unique solutions. Our globality, personal approach and our drive to expedite research timelines, makes us ideally suited to support our clients’ needs.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain.
Founded in 2008, we are a privately-held biotech company. We work with big pharma, biotech and academia across the world. Through a constant focus on high quality data, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.
To study gene delivery or biodistribution in pre-clinical models of neurodegeneration, we have developed a unique pipeline for quantitative whole-brain 3D imaging. By combining light sheet microscopy, AI-powered image analysis and cloud-based data reporting we enable visualisation and quantification of CNS targets, drug distribution and viral uptake across the intact mouse brain.
Certara accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. Our unique and regulatory-ready models for immunogenicity, immune-oncology, rare disease, vaccines and gene therapy are used by major pharmaceutical and emerging biotech companies.
PackGene Biotech, as an international AAV packaging supplier (one of the largest in the world), started up in Massachusetts. PackGene focuses on services of the rAAV-based gene therapy CDMO-from plasmid to rAAV in clinical-grade, rAAV packaging in research-grade, lentivirus packaging, vector cloning, etc. Our services aim to provide efficient, cost-effective, high-quality viral delivery solutions for gene and cell therapy, as well as clinical trials at various scale levels. PackGene has been building up its reputation by First-class Quality · Efficient Supply · Assured Service
Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals, tracking targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Over the past five years, PPD has conducted more than 40 gene therapy studies, utilizing multiple vectors and administration routes. Our experience in gene therapy crosses all therapeutic areas, with key strengths in neuroscience and rare diseases. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value.